Gilead

April 10, 2017April 10, 2017

FDA Approves Sovaldi and Harvoni for Pediatric Hepatitis C Patients

Hepatitis C, News

Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) were recently added to the list of approved medications for the treatment of hepatitis C virus (HCV) in pediatric patients ages 12 to 17 by the ... Read more

March 28, 2017March 28, 2017

European Public Health Alliance Joins Patent Opposition for HCV Treatment

Hepatitis C, News

The European Public Health Alliance (EPHA) is one of 30 civil society organizations from 17 European countries to file a coordinated patent opposition on sofosbuvir with the European Patent Office ... Read more

July 5, 2016July 5, 2016

MassHealth Expands Access to Hepatitis C Therapies Like Harvoni

Hepatitis C, News

Leaders in Massachusetts recently took steps to ensure that all members of MassHealth, the state’s health insurance program for low- and moderate-income residents, have access to medications to treat hepatitis C. Following months of negotiations, MassHealth ... Read more

April 21, 2016April 21, 2016

Positive Data for Hepatitis C Drugs Presented by Gilead, AbbVie Bode Well for Patients

News

Gilead Sciences recently announced that clinical trials involving a pan-genotypic protease inhibitor demonstrated promise in the treatment of a rare hepatitis C (HVC) patient population. The results were presented at The International Liver Congress (2016 ... Read more

November 5, 2015November 5, 2015

Two Hepatitis C Drugs Can Cause Liver Injury, FDA Warns

News

Federal health officials are cautioning patients and clinicians about the potential for life-threatening liver injury in two AbbVie drugs used for the treatment of advanced forms of hepatitis C. The Food and Drug ... Read more

June 22, 2015July 2, 2015

China Rejects Gilead Patent Bid On $1,000-A-Day Hepatitis C Drug Sovaldi (Sofobuvir)

News

In response to news that the Chinese government patent office has denied a request by Gilead Sciences for a key patent on the hepatitis C drug sofosbuvir (trade name Sovaldi) ... Read more

April 28, 2015April 28, 2015

Gilead’s Drugs Harvoni and Sovaldi Prove to Be Safe and Effective in Patients with Advanced Liver Disease Associated with HCV

Hepatitis C, News

Gilead Sciences, Inc. recently announced in a press release the promising results from several Phase 2 clinical trials assessing the use of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) and Sovaldi® (sofosbuvir ... Read more